A Maryland statute that protects veterinarians who recommend medical marijuana for animal patients takes effect this week, Marijuana Moment reports, creating a state-level legal shield for a practice that had previously sat in a regulatory gray zone.

The measure bars Maryland's veterinary licensing board from taking disciplinary action against a licensee solely for discussing or recommending medical marijuana as a treatment option for an animal patient. The statute stops short of authorizing veterinarians to dispense, administer or prescribe cannabis products and does not change the drug's federal Schedule I status under the Controlled Substances Act.

What does the statute actually do?

The text creates a safe harbor around the act of recommendation and discussion. A practitioner who raises cannabis as a treatment option with an owner, or who documents that recommendation in a medical record, cannot be sanctioned by the state licensing board on that basis alone. The protection attaches to the recommendation; it does not extend to activities that remain federally restricted, including dispensing a cannabis product in the clinic.

Why Maryland acted

State medical-cannabis statutes, and the adult-use programs that followed them, have generally defined "patient" in human terms only. Veterinary medicine was left without explicit guidance, and practitioners who discussed cannabis in the exam room faced uncertainty about how state boards and federal regulators would treat the conversation. Maryland's measure is among the first to address the veterinary side directly.

Companion-animal practice implications

For small-animal practitioners, the change resolves one specific risk: the license-protection question. It does not resolve several others. No cannabis product carries FDA Center for Veterinary Medicine approval for use in dogs, cats or other species. Toxicology data remain thin, particularly for dogs, where THC intoxication and, less commonly, fatal outcomes have been reported in the peer-reviewed literature. Practitioners who choose to recommend cannabis should document the conversation, obtain informed consent from the owner, and counsel clients on product quality, dosing uncertainty and the lack of regulatory approval.

Food-animal and public-health considerations

The bill's reach is companion-animal in practical effect. Veterinarians working with livestock, dairy or food-producing species face additional restrictions through the Animal Medicinal Drug Use Clarification Act and residue-tolerance rules administered by the FDA CVM. Cannabis recommendations in production-animal medicine raise concerns about milk and meat residues, withdrawal times and worker safety that the Maryland statute does not address.

What practitioners should not assume

The state protection does not authorize:

• Dispensing cannabis products from the clinic.
• Prescribing under a human medical-cannabis program on behalf of an animal.
• Bypassing federal Controlled Substances Act restrictions on Schedule I substances.

Clients who pursue cannabis for an animal should be referred to their own physician for human medical-cannabis certifications where applicable and directed to products labeled for veterinary use where such products exist under state law.

What to watch

Maryland's statute will draw close attention from state boards and veterinary associations in other jurisdictions considering whether to follow the same approach. Whether additional state legislatures adopt comparable language, and whether the FDA CVM or DEA eventually act on scheduling or veterinary product approvals, will determine whether Maryland's safe harbor remains a single-state measure or becomes a working template.